With a market cap of $31.2 billion, Zoetis Inc. (ZTS) is the world's leading animal health company, dedicated to advancing animal care through innovative medicines, vaccines, diagnostics, biopharmaceuticals, and digital solutions. With nearly 75 years of scientific expertise and a presence in over 100 countries, Zoetis empowers veterinarians, livestock producers, and pet owners by pioneering solutions to predict, prevent, detect, and treat animal illness.
The Parsippany, New Jersey-based company is slated to announce its fiscal Q2 2026 results before the market opens on Thursday, Aug. 6. Ahead of the event, analysts expect Zoetis to report an adjusted EPS of $1.85, up 5.1% from $1.76 in the year-ago quarter. It has surpassed Wall Street's bottom-line estimates in three of the past four quarterly reports while missing on another occasion.
More Top Stocks Daily: Go behind Wall Street’s hottest headlines with Barchart’s Active Investor newsletter.
For fiscal 2026, analysts predict the animal health company to report adjusted EPS of $6.87, a 7.2% rise from $6.41 in fiscal 2025.
www.barchart.com Shares of Zoetis have fallen 51.2% over the past 52 weeks, lagging behind both the S&P 500 Index's ($SPX) 21.3% increase and the State Street Health Care Select Sector SPDR ETF's (XLV) 19.4% gain over the same period.
www.barchart.com Zoetis shares tumbled 21.5% on May 7 after the company lowered its full-year 2026 guidance, forecasting adjusted EPS of $6.85 - $7 and revenue of $9.68 billion - $9.96 billion, both below market expectations. The weaker outlook followed a challenging Q1 2026, with U.S. revenue declining 8% year-over-year to $1.1 billion and U.S. companion animal product sales falling 11% due to intense competition and softer demand, despite total revenue increasing 3% year-over-year to $2.3 billion. Also, while adjusted EPS grew 9% to $1.53, it missed consensus estimates, reinforcing investor concerns.
Analysts' consensus rating on ZTS stock is cautiously optimistic, with an overall "Moderate Buy" rating. Among 18 analysts covering the stock, eight recommend a "Strong Buy,” one has a "Moderate Buy" rating, and nine give a "Hold" rating. The average analyst price target for Zoetis is $110.19, indicating a potential upside of 47.8% from the current levels.
On the date of publication, Sohini Mondal did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.
More news from Barchart
Here’s the ‘Baby Buffett’ Investing Story I Meant to Write Before BlackRock Distracted Me. 2 Reasons to Feel Bullish on GOOGL Stock Ahead of Alphabet’s Q2 Earnings Stocks Slip Before the Open as Chipmakers Extend Slide, U.S. Retail Sales Data and Earnings on Tap This Dividend Stock Trading Near Multi-Year Lows Is a Risky Buy With Significant Upside Potential